Eli Lilly and Company
LLYNYSETrackedESG Rated: 2/2 ProvidersMarket Data VerifiedHealth CarePharmaceuticalsMSCI: ASustainalytics: 20.0 · Medium
- Coverage
- Rated universe Carries an MSCI or Sustainalytics observation.
- ESG profile reviewed
- Last editorial update to this profile.
- Quote
- Last verified closeObservation time is shown beside the price.
- Methodology
- How we rateProvider ratings are shown separately, never blended.
Market overview
Up+USD 30.90 (+2.68%) Day change
The market is closed. This is the last verified closing quote, not an intraday price.
- Open
- USD 1,156.67
- Previous close
- USD 1,150.99
- Day high
- USD 1,197.75
- Day low
- USD 1,151.01
- Volume
- 2,408,724
- Market cap
- USD 1,053,940,252,672
View Chart Data
| Date and time | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| USD 750.57 | USD 753.00 | USD 743.17 | USD 746.98 | 2,910,100 | |
| USD 737.67 | USD 740.00 | USD 712.05 | USD 714.59 | 5,136,400 | |
| USD 931.17 | USD 932.00 | USD 900.90 | USD 924.37 | 4,373,400 | |
| USD 1,041.00 | USD 1,066.65 | USD 1,038.00 | USD 1,059.70 | 4,266,700 | |
| USD 1,002.84 | USD 1,012.00 | USD 979.18 | USD 982.22 | 2,569,700 | |
| USD 1,074.64 | USD 1,085.73 | USD 1,072.71 | USD 1,076.98 | 932,800 | |
| USD 1,058.00 | USD 1,083.36 | USD 1,058.00 | USD 1,081.00 | 2,380,200 | |
| USD 1,029.11 | USD 1,029.69 | USD 1,004.14 | USD 1,023.80 | 3,300,200 | |
| USD 1,024.87 | USD 1,059.84 | USD 1,012.00 | USD 1,038.27 | 3,592,200 | |
| USD 1,044.62 | USD 1,056.20 | USD 1,013.00 | USD 1,017.97 | 3,094,300 | |
| USD 978.92 | USD 981.17 | USD 925.25 | USD 930.35 | 5,637,500 | |
| USD 893.49 | USD 924.14 | USD 892.14 | USD 919.77 | 3,464,200 | |
| USD 911.67 | USD 920.00 | USD 898.15 | USD 903.99 | 2,836,600 | |
| USD 948.95 | USD 984.45 | USD 943.80 | USD 963.33 | 4,352,400 | |
| USD 1,000.61 | USD 1,003.00 | USD 978.87 | USD 988.09 | 2,016,000 | |
| USD 1,059.50 | USD 1,093.28 | USD 1,053.51 | USD 1,078.78 | 2,655,600 | |
| USD 1,120.49 | USD 1,122.33 | USD 1,088.66 | USD 1,098.57 | 4,470,500 | |
| USD 1,232.88 | USD 1,249.45 | USD 1,222.77 | USD 1,235.56 | 2,933,800 | |
| USD 1,173.91 | USD 1,175.00 | USD 1,153.50 | USD 1,163.01 | 1,555,800 | |
| USD 1,174.00 | USD 1,216.94 | USD 1,138.43 | USD 1,169.86 | 6,445,700 | |
| USD 1,245.81 | USD 1,292.65 | USD 1,240.54 | USD 1,280.34 | 4,541,800 | |
| USD 1,274.13 | USD 1,280.28 | USD 1,243.23 | USD 1,244.40 | 2,621,400 | |
| USD 1,150.61 | USD 1,158.44 | USD 1,138.31 | USD 1,149.36 | 2,218,900 | |
| USD 1,146.15 | USD 1,180.53 | USD 1,139.26 | USD 1,170.14 | 2,252,535 |
Company Profile & Business Model Overview
Eli Lilly is a leading pharmaceutical company known for diabetes, oncology, and immunology treatments. The company has made insulin more affordable while developing breakthrough therapies for obesity and Alzheimer’s.
Sustainability Strengths & Catalysts (Pros)
- Lilly has a history of being a socially responsible company
- The company is committed to environmental sustainability, with a goal to reduce its greenhouse gas emissions by 25% by 2025
- Lilly has a strong focus on diversity and inclusion, with programs in place to support employees from underrepresented groups
Material Risks & Governance Concerns (Cons)
- The company's share price is down 7% over the past year
- The company is facing several lawsuits alleging that it failed to warn patients of the risks associated with its diabetes drug and dulaglutide
Related ESG Peer Equities
Companies in Health Care evaluated across carbon intensity, social metrics, and board governance.
ESG & Sustainability Rating Breakdown
Synthesized multi-provider rating across Environmental, Social, and Corporate Governance dimensions.
Audited Methodology
MSCI ESG industry rating benchmark.
Medium
Data integrity and methodology
MSCI and Sustainalytics ratings are shown separately with their own observation dates; they are not blended into one score, and providers can disagree. Market quotes are delayed or last-close values, and every snapshot states its source and observation time. Read the full rating methodology.
Financial & Valuation Fundamentals
Core balance sheet and equity valuation metrics sourced from corporate filings.
Audited Financials
Related ESG Financial Tools & Modeling
ESG Investment Growth Calculator
Project compound future portfolio values versus traditional index benchmarks.
Launch Tool →
Portfolio Carbon Footprint Calculator
Translate your investment capital into financed greenhouse gas emissions.
Launch Tool →
Green Mortgage Calculator
Calculate interest rate discounts on energy-efficient certified homes.
Launch Tool →
Featured Sustainable Investment Research & Guides
Top 12 Impact Investing Apps & Platforms (Reviewed)
Comprehensive review of the best ESG micro-investing and direct indexing apps.
Biblically Responsible Investing (BRI): Top Stocks & Funds
Faith-based screening criteria, ESG alignment, and values-based portfolio strategies.
Top Desalination & Clean Water Infrastructure Stocks
Invest in global clean water purification, reverse osmosis, and municipal utilities.
Best Certified B-Corp Banks & Sustainable Banking
How to align your everyday cash reserves with social and climate impact standards.
Frequently Asked Questions
Direct answers on sustainability scores, risk methodologies, and peer rankings.
What is Eli Lilly and Company (LLY)'s ESG rating and sustainability score?
Eli Lilly and Company (LLY) currently holds an MSCI ESG rating of A and a Sustainalytics ESG Risk Score of 20.0 (Audited Risk Band). Ratings evaluate environmental emissions, labor standards, board independence, and regulatory compliance.
Is Eli Lilly and Company considered an ESG leader or laggard in Health Care?
Eli Lilly and Company is classified as an Average ESG performer by MSCI with a A rating, indicating performance in line with mainstream sector peers with opportunities for further disclosure and risk management.
What are the main ESG risks and controversies for Eli Lilly and Company?
Key material risks for Eli Lilly and Company include: The company's share price is down 7% over the past year; The company is facing several lawsuits alleging that it failed to warn patients of the risks associated with its diabetes drug and dulaglutide. Investors should evaluate whether corporate mitigation plans adequately address these vulnerabilities.
How does The Impact Investor evaluate ESG stock profiles?
The Impact Investor presents audited third-party ratings from MSCI and Sustainalytics alongside delayed market data and financial fundamentals. We do not blend ratings into proprietary black-box scores, and ratings are never modified by advertising or affiliate relationships.